Supporting Clinical Research in Schizophrenia

Advancing Scientific Innovation in Schizophrenia

VeraSci brings decades of experience and deep scientific expertise to clinical trials in schizophrenia. Schizophrenia is a complex, multi-faceted neuropsychiatric disorder and one of the leading causes of functional disability in the world. In addition to targeting the characteristic positive symptoms (e.g., delusions, hallucinations) of schizophrenia, many trials are testing novel agents that target other functionally disabling aspects of this disorder, including negative symptoms and cognitive impairment. VeraSci has been an industry leader in supporting trials aimed at addressing cognitive impairment associated with schizophrenia through the implementation of the gold-standard MATRICS Consensus Cognitive Battery (MCCB) and key co-primary functional capacity outcome measures. We are also leading trials aimed at improving negative symptoms (e.g., avolition, affective flattening) using gold-standard rating scales, as well as cutting-edge interview- and performance-based measures.

Our highly experienced team brings decades of clinical research and treatment experience to support state-of-the-art clinical trials in schizophrenia. We offer comprehensive start-to-finish services for clinical trials including trial design and regulatory strategy consultation, novel method development, implementation of rigorous assessment and quality assurance procedures, linguistics for multi-national trials, and interpretation of trial results.